• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

膜联蛋白-4对转移性尿路上皮癌铂类化疗疗效的影响

Impact of Membranous Nectin-4 on Outcomes of Platinum-Based Chemotherapy in Metastatic Urothelial Carcinoma.

作者信息

Hsueh Fu-Jen, Wang Chung-Chieh, Guo Jhe-Cyuan, Chueh Shih-Chieh, Tsai Yu-Chieh

机构信息

Department of Oncology, National Taiwan University Hospital, Taipei 100, Taiwan.

Department of Pathology, National Taiwan University Hospital, Taipei 100, Taiwan.

出版信息

Cancers (Basel). 2025 Jan 27;17(3):433. doi: 10.3390/cancers17030433.

DOI:10.3390/cancers17030433
PMID:39941802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11815779/
Abstract

Metastatic urothelial carcinoma (mUC) is a highly aggressive malignancy [...].

摘要

转移性尿路上皮癌（mUC）是一种侵袭性很强的恶性肿瘤[...]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cd5/11815779/a7639ff26d98/cancers-17-00433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cd5/11815779/a7639ff26d98/cancers-17-00433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cd5/11815779/a7639ff26d98/cancers-17-00433-g001.jpg

相似文献

1
Impact of Membranous Nectin-4 on Outcomes of Platinum-Based Chemotherapy in Metastatic Urothelial Carcinoma.膜联蛋白-4对转移性尿路上皮癌铂类化疗疗效的影响
Cancers (Basel). 2025 Jan 27;17(3):433. doi: 10.3390/cancers17030433.
2
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.膜层粘连蛋白 4 的表达在尿路上皮癌转移过程中经常下降，并与恩福妥单抗 vedotin 的耐药性相关。
Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764.
3
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.转移性膀胱癌变异组织中 Nectin-4 和 Trop-2 的表达和亚细胞定位：一项快速尸检研究。
Clin Genitourin Cancer. 2023 Dec;21(6):669-678. doi: 10.1016/j.clgc.2023.05.014. Epub 2023 May 25.
4
The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.转移性尿路上皮癌一线靶向治疗的快速演变格局：一项系统综述
Oncologist. 2021 Aug;26(8):e1381-e1394. doi: 10.1002/onco.13827. Epub 2021 Jun 11.
5
The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer.抗体药物偶联物在尿路上皮癌中的作用：局部晚期和转移性尿路上皮癌治疗的最新进展综述
Clin Med Insights Oncol. 2024 Dec 15;18:11795549241290787. doi: 10.1177/11795549241290787. eCollection 2024.
6
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.铂类药物治疗转移性疾病后，先前接受过铂类化疗的转移性尿路上皮癌中铂类药物再挑战的疗效。
Oncologist. 2021 Dec;26(12):1026-1034. doi: 10.1002/onco.13925. Epub 2021 Aug 17.
7
Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?恩杂鲁胺治疗转移性尿路上皮癌：最终的解决方案？
Front Oncol. 2023 Sep 13;13:1254906. doi: 10.3389/fonc.2023.1254906. eCollection 2023.
8
Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States.美国局部晚期或转移性尿路上皮癌患者的真实世界生存率和经济负担
Urol Oncol. 2025 Mar;43(3):189.e9-189.e18. doi: 10.1016/j.urolonc.2024.11.010. Epub 2024 Dec 14.
9
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.与在检查点抑制剂治疗后转移性尿路上皮癌中重新使用化疗相比，恩杂鲁胺对其有持久反应。
Target Oncol. 2024 May;19(3):401-410. doi: 10.1007/s11523-024-01047-y. Epub 2024 Mar 28.
10
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma.单药恩扎妥昔单抗治疗晚期尿路上皮癌患者的真实世界疗效
Clin Genitourin Cancer. 2025 Feb;23(1):102287. doi: 10.1016/j.clgc.2024.102287. Epub 2024 Dec 6.

本文引用的文献

1
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.泌尿生殖系统恶性肿瘤中Nectin-4的阳性表达：一项系统综述。
JCO Precis Oncol. 2024 Dec;8:e2400470. doi: 10.1200/PO-24-00470. Epub 2024 Dec 3.
2
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.在美国，一线依维莫司丁联合帕博利珠单抗治疗转移性尿路上皮癌的成本效果分析。
Front Immunol. 2024 Sep 9;15:1464092. doi: 10.3389/fimmu.2024.1464092. eCollection 2024.
3
Contemporary survival in metastatic bladder cancer patients: A population-based study.
转移性膀胱癌患者的当代生存状况：一项基于人群的研究。
Int J Cancer. 2024 Nov 15;155(10):1762-1768. doi: 10.1002/ijc.35077. Epub 2024 Jul 3.
4
Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.在实体瘤中扩增频繁，并预测转移性尿路上皮癌对恩福妥单抗 Vedotin 的反应。
J Clin Oncol. 2024 Jul 10;42(20):2446-2455. doi: 10.1200/JCO.23.01983. Epub 2024 Apr 24.
5
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
6
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.顺铂与卡铂为基础的化疗联合阿替利珠单抗在膀胱癌中的免疫调节作用及改善结局。
Cell Rep Med. 2024 Feb 20;5(2):101393. doi: 10.1016/j.xcrm.2024.101393. Epub 2024 Jan 26.
7
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.纳武利尤单抗联合吉西他滨-顺铂治疗晚期尿路上皮癌。
N Engl J Med. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22.
8
Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.上尿路尿路上皮癌的转录组谱分析：膀胱癌共识分类的相关性、分子异质性和差异免疫特征。
Mod Pathol. 2023 Nov;36(11):100300. doi: 10.1016/j.modpat.2023.100300. Epub 2023 Aug 7.
9
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.膜层粘连蛋白 4 的表达在尿路上皮癌转移过程中经常下降，并与恩福妥单抗 vedotin 的耐药性相关。
Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764.
10
Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.帕博利珠单抗治疗的尿路上皮癌患者中 PD-L1 和 Nectin-4 的表达。
Clin Transl Oncol. 2022 Mar;24(3):568-577. doi: 10.1007/s12094-021-02717-3. Epub 2021 Oct 23.